Case Report: Contrasting BCL2 Upregulation With Venetoclax in a Case of Refractory Lymphomatoid Papulosis and Progressive Chronic Lymphocytic Leukemia
A 57-year-old man affected by high-risk progressive chronic lymphocytic leukemia (CLL), primary resistant to first-line chemoimmunotherapy, developed a type A lymphomatoid papulosis (LyP) during a second progression of CLL. The two blood tumor entities were clonally unrelated. LyP presented with a d...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-09-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.729106/full |
id |
doaj-e0536357efc5428394fe24aa2e6a1873 |
---|---|
record_format |
Article |
spelling |
doaj-e0536357efc5428394fe24aa2e6a18732021-09-09T06:56:45ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-09-011110.3389/fonc.2021.729106729106Case Report: Contrasting BCL2 Upregulation With Venetoclax in a Case of Refractory Lymphomatoid Papulosis and Progressive Chronic Lymphocytic LeukemiaValerio GuarenteGiovanni MartinoErica DorilloFilomena De FalcoChiara RompiettiDaniele SorciniMariangela BrognaValeria CardinaliStefano AscaniAndrea MarraPaolo SportolettiA 57-year-old man affected by high-risk progressive chronic lymphocytic leukemia (CLL), primary resistant to first-line chemoimmunotherapy, developed a type A lymphomatoid papulosis (LyP) during a second progression of CLL. The two blood tumor entities were clonally unrelated. LyP presented with a diffuse (>90% body surface area) cutaneous rash and was characterized by intensely pruriginous dusky nodules (n = 10) and red flat-topped papules (n = 60). No response to topical corticosteroids and psoralen plus ultraviolet A (PUVA) phototherapy was observed. In order to effectively treat progressive TP53-mutated CLL, the potent BCL2 inhibitor, venetoclax, was initiated with no treatment-related complications. While CLL only achieved a partial response, a complete remission of LyP-associated cutaneous rash and of the intractable pruritus was obtained within 2 months from venetoclax initiation. BCL2 immunostaining of the original cutaneous specimen showed a strong over-expression of the anti-apoptotic protein, restricted to CD30+ lymphoid cells and reactive microenvironment. At 12 months follow-up, the patient is still in complete remission of LyP. Our findings underline the probable pathogenic role of BCL2 in LyP and the potential therapeutic efficacy of venetoclax for the treatment of this primary cutaneous CD30+ lymphoproliferative disorder, especially in the setting of severe and refractory disease.https://www.frontiersin.org/articles/10.3389/fonc.2021.729106/fullT-cell lymphomachronic lymphocytic leukemiavenetoclax (BCL2 inhibitor)lymphomatoid papulosis (LyP)lymphomatoid papulosis treatment |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Valerio Guarente Giovanni Martino Erica Dorillo Filomena De Falco Chiara Rompietti Daniele Sorcini Mariangela Brogna Valeria Cardinali Stefano Ascani Andrea Marra Paolo Sportoletti |
spellingShingle |
Valerio Guarente Giovanni Martino Erica Dorillo Filomena De Falco Chiara Rompietti Daniele Sorcini Mariangela Brogna Valeria Cardinali Stefano Ascani Andrea Marra Paolo Sportoletti Case Report: Contrasting BCL2 Upregulation With Venetoclax in a Case of Refractory Lymphomatoid Papulosis and Progressive Chronic Lymphocytic Leukemia Frontiers in Oncology T-cell lymphoma chronic lymphocytic leukemia venetoclax (BCL2 inhibitor) lymphomatoid papulosis (LyP) lymphomatoid papulosis treatment |
author_facet |
Valerio Guarente Giovanni Martino Erica Dorillo Filomena De Falco Chiara Rompietti Daniele Sorcini Mariangela Brogna Valeria Cardinali Stefano Ascani Andrea Marra Paolo Sportoletti |
author_sort |
Valerio Guarente |
title |
Case Report: Contrasting BCL2 Upregulation With Venetoclax in a Case of Refractory Lymphomatoid Papulosis and Progressive Chronic Lymphocytic Leukemia |
title_short |
Case Report: Contrasting BCL2 Upregulation With Venetoclax in a Case of Refractory Lymphomatoid Papulosis and Progressive Chronic Lymphocytic Leukemia |
title_full |
Case Report: Contrasting BCL2 Upregulation With Venetoclax in a Case of Refractory Lymphomatoid Papulosis and Progressive Chronic Lymphocytic Leukemia |
title_fullStr |
Case Report: Contrasting BCL2 Upregulation With Venetoclax in a Case of Refractory Lymphomatoid Papulosis and Progressive Chronic Lymphocytic Leukemia |
title_full_unstemmed |
Case Report: Contrasting BCL2 Upregulation With Venetoclax in a Case of Refractory Lymphomatoid Papulosis and Progressive Chronic Lymphocytic Leukemia |
title_sort |
case report: contrasting bcl2 upregulation with venetoclax in a case of refractory lymphomatoid papulosis and progressive chronic lymphocytic leukemia |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Oncology |
issn |
2234-943X |
publishDate |
2021-09-01 |
description |
A 57-year-old man affected by high-risk progressive chronic lymphocytic leukemia (CLL), primary resistant to first-line chemoimmunotherapy, developed a type A lymphomatoid papulosis (LyP) during a second progression of CLL. The two blood tumor entities were clonally unrelated. LyP presented with a diffuse (>90% body surface area) cutaneous rash and was characterized by intensely pruriginous dusky nodules (n = 10) and red flat-topped papules (n = 60). No response to topical corticosteroids and psoralen plus ultraviolet A (PUVA) phototherapy was observed. In order to effectively treat progressive TP53-mutated CLL, the potent BCL2 inhibitor, venetoclax, was initiated with no treatment-related complications. While CLL only achieved a partial response, a complete remission of LyP-associated cutaneous rash and of the intractable pruritus was obtained within 2 months from venetoclax initiation. BCL2 immunostaining of the original cutaneous specimen showed a strong over-expression of the anti-apoptotic protein, restricted to CD30+ lymphoid cells and reactive microenvironment. At 12 months follow-up, the patient is still in complete remission of LyP. Our findings underline the probable pathogenic role of BCL2 in LyP and the potential therapeutic efficacy of venetoclax for the treatment of this primary cutaneous CD30+ lymphoproliferative disorder, especially in the setting of severe and refractory disease. |
topic |
T-cell lymphoma chronic lymphocytic leukemia venetoclax (BCL2 inhibitor) lymphomatoid papulosis (LyP) lymphomatoid papulosis treatment |
url |
https://www.frontiersin.org/articles/10.3389/fonc.2021.729106/full |
work_keys_str_mv |
AT valerioguarente casereportcontrastingbcl2upregulationwithvenetoclaxinacaseofrefractorylymphomatoidpapulosisandprogressivechroniclymphocyticleukemia AT giovannimartino casereportcontrastingbcl2upregulationwithvenetoclaxinacaseofrefractorylymphomatoidpapulosisandprogressivechroniclymphocyticleukemia AT ericadorillo casereportcontrastingbcl2upregulationwithvenetoclaxinacaseofrefractorylymphomatoidpapulosisandprogressivechroniclymphocyticleukemia AT filomenadefalco casereportcontrastingbcl2upregulationwithvenetoclaxinacaseofrefractorylymphomatoidpapulosisandprogressivechroniclymphocyticleukemia AT chiararompietti casereportcontrastingbcl2upregulationwithvenetoclaxinacaseofrefractorylymphomatoidpapulosisandprogressivechroniclymphocyticleukemia AT danielesorcini casereportcontrastingbcl2upregulationwithvenetoclaxinacaseofrefractorylymphomatoidpapulosisandprogressivechroniclymphocyticleukemia AT mariangelabrogna casereportcontrastingbcl2upregulationwithvenetoclaxinacaseofrefractorylymphomatoidpapulosisandprogressivechroniclymphocyticleukemia AT valeriacardinali casereportcontrastingbcl2upregulationwithvenetoclaxinacaseofrefractorylymphomatoidpapulosisandprogressivechroniclymphocyticleukemia AT stefanoascani casereportcontrastingbcl2upregulationwithvenetoclaxinacaseofrefractorylymphomatoidpapulosisandprogressivechroniclymphocyticleukemia AT andreamarra casereportcontrastingbcl2upregulationwithvenetoclaxinacaseofrefractorylymphomatoidpapulosisandprogressivechroniclymphocyticleukemia AT paolosportoletti casereportcontrastingbcl2upregulationwithvenetoclaxinacaseofrefractorylymphomatoidpapulosisandprogressivechroniclymphocyticleukemia |
_version_ |
1717761335413964800 |